Three-year risk of high-grade CIN for women aged 30 years or older who undergo baseline Pap cytology and HPV co-screening.

Ming GuoAbha KhannaJianping WangMarilyn A DawlettTeresa L KologinczakGenevieve R LyonsRoland L BassettNour SneigeYun GongTherese B Bevers

Published in: Cancer cytopathology (2017)

Pap cytology and HPV cotesting are valuable for stratifying CIN-3 risk. Pap cytology and HPV co-screening at a 3-year screening interval appears to carry a low risk of CIN-3 for women who have a baseline Pap-/HPV- cotesting result. Cancer Cytopathol 2017;125:644-51. © 2017 American Cancer Society.

Keyphrases

high grade
low grade
papillary thyroid
cervical cancer screening
polycystic ovary syndrome
squamous cell
pregnancy outcomes
squamous cell carcinoma
type diabetes
metabolic syndrome
pregnant women
insulin resistance
childhood cancer
adipose tissue
young adults